The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration.
Open accessAbstract
The CDK inhibitor p21 (WAF-1/CIP-1/SDI-1) has been implicated in DNA damage-induced p53-mediated G1 arrest, as well as in physiological processes, such as cell differentiation and senescence, that do not involve p53 function. To determine the impact of p21 on normal development and cell-cycle regulation in vivo, we have generated transgenic mice that abundantly express p21 specifically in hepatocytes. During postnatal liver development, when transgenic p-21 protein becomes detectable, hepatocyte proliferation is inhibited dramatically. This disturbance causes a reduction in the overall number of adult hepatocytes, resulting in aberrant tissue organization, runted liver and body growth, and increased mortality. The transgenic p21 protein is associated with most, if not all, of the cyclin D1-CDK4 in liver but not significantly with other cyclin/CDK proteins, indicating the importance of cyclin D1-CDK4 function in normal liver development. The appearance of large polyploid nuclei in some hepatocytes indicates that p21 may also cause arrest during the G2 phase of the cell cycle. Significantly, partial hepatectomy failed to stimulate hepatocytes to proliferate in p21 transgenic animals. These results provide the first in vivo evidence that appropriate p21 levels are critical in normal development and further implicate p21 in the control of multiple cell-cycle phases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The proliferation of p21 positive hepatocytes is irreversibly inhibited49 making it unlikely that p21 positive hepatocytes contribute to regeneration here.”
From Hepatic progenitor cells of biliary origin with liver repopulation capacity (2015) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Experimental pathology of the liver
Higgins, G. (1931) · Medical Entomology and Zoology · Cited by 4,057
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691
Self-citationA new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,288
Inhibitors of mammalian G1 cyclin-dependent kinases.Preprint
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,242
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,675
Flagged first, then by citations
Research works printed but not linked: 3
- 10.1128/MCB.6.12.4697 · DOI
- 1992, The liver as a stem cell lineage system., Am. J. Physiol., 263, 139
- 1994, Induction of p21 (WAF1/CIP1) during differentiation., Oncogene, 9, 3389
Cited by
Sorted by citations
Niculescu, A. B., Chen, X., Smeets, M. F. M. A., Hengst, L., Prives, C. L., & Reed, S. I. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.629 · Cited by 725
The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.
Hakem, R., de la Pompa, J. L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81302-1 · Cited by 680
Hepatic progenitor cells of biliary origin with liver repopulation capacity
Lu, W.-Y., Bird, T. G., Boulter, L., Tsuchiya, A., Cole, A. M., Hay, T., Guest, R. V., Wojtacha, D., Man, T. Y., Mackinnon, A., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3203 · Cited by 479
Weeda, G., Donker, I., de Wit, J., Morreau, H., Janssens, R. C., Vissers, C. J., Nigg, A. L., STEEG, H. V., Bootsma, D., & Hoeijmakers, J. H. J. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00190-4 · Cited by 386
Ye, H.-G., Kelly, T., Samadani, U., Lim, L., Rubio, S., Overdier, D., Roebuck, K., & Costa, R. H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1626 · Cited by 117
Metadata
- Authors
- Wu, H., Wade, M., Krall, L., Grisham, J., Xiong, Y., & Van Dyke, T.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1996-02-01
- Volume
- 10
- Issue
- 3
- Pages
- 245-260
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4300612151
- Cited by
- 234
- References
- 75
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 4 · 2015: 5 · 2014: 2 · 2013: 4 · 2012: 1
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5r01dk042910-04)
- National Cancer Institute (R01CA065572, CA 65572, R01CA046283, CA-46283)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-42910)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Keywords
- p21, cyclin-dependent kinase inhibitors, hepatocytes, postnatal liver development, liver regeneration, cell cycle arrest, cyclin D1/CDK4, hepatocyte proliferation, transgenic mice, partial hepatectomy, G2 cell cycle arrest, polyploidy, p53-independent function
- MeSH terms
- Animals, Base Sequence, Cell Cycle, Cell Division, DNA, Enzyme Inhibitors, Hepatectomy, Liver, Liver Regeneration, Mice, Transgenic, Molecular Sequence Data, Prealbumin, Proto-Oncogene Proteins, Oncogene Proteins, Cyclins, Gene Targeting, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
